GlassScriptPhysician profile
Natalie Esparza
NPI 1710914718
$5,418.30
in general payments reported to CMS, 2019-2025
38 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $556 · 2021: $657 · 2022: $597 · 2023: $668 · 2024: $1,002 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,920.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,252.49 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Pfizer INC. | $652.15 | 2019-2025 | |
| Abbvie INC. | $554.90 | 2019-2025 | |
| Medtronic, INC. | $443.43 | 2022-2025 | Interstim |
| Janssen Biotech, INC. | $319.29 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $270.67 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $238.50 | 2019-2025 | General - Kidney Stone Disease, Rezum Generator, Spaceoar Vue System - 10ml |
| Myriad Genetic Laboratories, INC. | $207.27 | 2020-2024 | Prolaris |
| Axonics, INC. | $169.85 | 2020-2023 | Bulkamid |
| Blue Earth Diagnostics | $124.26 | 2021-2025 | Posluma |
| Antares Pharma, INC. | $83.90 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Accord Healthcare, INC. | $83.87 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.29 | 2025 | |
| Ferring Pharmaceuticals INC. | $67.65 | 2020-2025 | Adstiladrin |
| Sun Pharmaceutical Industries INC. | $59.66 | 2022-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $59.33 | 2023-2024 | Pylarify |
| Myovant Sciences INC. | $58.42 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $56.76 | 2024-2025 | Trelstar |
| Urovant Sciences INC | $56.39 | 2022 | |
| Merck Sharp & Dohme LLC | $51.10 | 2024-2025 | Keytruda |
| Endo Pharmaceuticals INC. | $48.29 | 2019-2023 | Xiaflex |
| Allergan, INC. | $46.03 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $42.37 | 2019-2023 | Provenge |
| Travere Therapeutics, INC. | $41.89 | 2019-2020 | |
| Ambu INC. | $38.24 | 2020-2023 | |
| Vertex Pharmaceuticals Incorporated | $37.84 | 2024-2025 | |
| Urogen Pharma, INC. | $36.32 | 2025 | |
| Janssen Scientific Affairs, LLC | $30.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.53 | 2025 | |
| Teleflex LLC | $27.24 | 2025 | Urolift |
| Tolmar Pharmaceuticals, INC. | $26.69 | 2019-2021 | |
| Endo USA, INC. | $22.57 | 2024 | Xiaflex |
| Civco Medical Instruments | $20.13 | 2024 | |
| Trevena, INC. | $19.04 | 2021 | |
| Clarus Therapeutics INC. | $18.13 | 2021 | |
| Cook Medical LLC | $17.97 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.01 | 2025 | Azmiro |
| Coloplast Corp | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Esparza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.